CME Resource Center |

Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment FREE TO VIEW

Fernando J. Martinez, MD; Kevin R. Flaherty, MD
Author and Funding Information

Editor's Note: This is one in a series of Elsevier and CHEST sponsored activities with CME. The readers can view the video and claim CME.

aDivision of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY

bDivision of Pulmonary and Critical Care Medicine, and Idiopathic Pulmonary Fibrosis Foundation Clinical Care Site, University of Michigan, Ann Arbor, MI

CORRESPONDENCE TO: Fernando J. Martinez, MD, 530 E 70th St, M-522, New York, NY 10021

Copyright 2017, . All Rights Reserved.

Chest. 2017;151(5):1173-1174. doi:10.1016/j.chest.2017.03.017
Text Size: A A A
Published online

As seen in this CME online activity (available at http://courses.elseviercme.com/chest16/647e), idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. It is the most common form of idiopathic interstitial pneumonia in adults. Its prevalence among US Medicare beneficiaries has more than doubled in the past 14 years. With the approval of two agents that reduce functional decline and disease progression, and the 2015 update of the American Thoracic Society guidelines on the treatment of IPF, the options for appropriate clinical management of the disease have become well defined. Early diagnosis and early initiation of treatment are of critical importance for long-term clinical outcomes. The diagnostic process, which may require a multidisciplinary team of experts, is centered on excluding systemic diseases and exposures and identifying a pattern of usual interstitial pneumonia on high-resolution CT or surgical lung biopsy results. Familiarity with the 2015 American Thoracic Society guidelines is critical with respect to both the treatments that the guidelines recommend and those that they advise against. Standard immunosuppressive therapy is no longer indicated, whereas pirfenidone, nintedanib, and antacid therapy are all conditionally recommended for use. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors. An early referral to an interstitial lung disease center offers the advantages of comprehensive diagnostic and disease-management expertise, potential enrollment in a clinical trial, and evaluation for transplantation.

It is the policy of The Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflict of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: F. J. M. is a consultant/advisor for Adept Pharma & Bioscience, AstraZeneca, Boehringer Ingelheim GmbH, Clarion Healthcare, Concert Pharmaceuticals, Inc., Genentech, Inc., GSK group of companies, Integritas, Unity/Medical Leverage, Mereo BioPharma Group PLC, Novartis AG, ProterixBio, Inc., and Theravance Biopharma. He has received grant/research support from Afferent Pharmaceuticals, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Biogen, Gilead, GSK group of companies, and Veracyte, Inc. He is on the speakers’ bureau for AstraZeneca, Boehringer Ingelheim GmbH, Novartis AG, and WebMD LLC. He has received royalties/patents from UpToDate, Inc. K. R. F. is a consultant/advisor for Aeolus Pharmaceuticals, Boehringer Ingelheim GmbH, FibroGen, Inc., Genentech, Inc., ImmuneWorks, PharmAkea Therapeutics, The Degge Group Ltd., and Veracyte, Inc. He has received grant/research support from Afferent Pharmaceuticals, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., and Genentech, Inc. Lyerka Miller, PhD, Sandy Breslow, Alison Kemp, and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

This activity has been designed to meet the educational needs of health-care professionals involved in the diagnosis, treatment, or management of patients with IPF.

On completion of this activity, participants will be better able to do the following:

  • Implement multidisciplinary clinical and imaging approaches to achieve more timely and accurate diagnosis of IPF

  • Develop IPF treatment strategies based on key guideline recommendations and examine the supporting clinical trial data

  • Describe key elements of an individualized approach to IPF treatment that involves shared decision-making

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543